法托他汀通过靶向SCAP/SREBP通路促进铁死亡及抑制ARID1A缺失型非小细胞肺癌

陈鑫鸿, 张雪, 刘婷, 张淑敏, 马雨鹏, 来佳辉, 章子晗, 池永斌

Fatostatin targets SCAP/SREBP pathway to inhibit ARID1A-deficient non-small cell lung cancer by promoting ferroptosis

Chen Xinhong, Zhang Xue, Liu Ting, Zhang Shumin, Ma Yupeng, Lai Jiahui, Zhang Zihan, Chi Yongbin

图3 ARID1A缺失的NSCLC细胞对法托他汀敏感性的变化 Note： A. Dose-response curves of fatostatin in WT and ARID1A-KO A549 cells. B/C. Neutral lipid droplets in the WT and KO groups after fatostatin treatment (5 or 10 μmol·L-1, 24 h) by Oil Red O staining (B) and quantification of Oil Red O-positive area (C). D. TCHO levels after 24 h of fatostatin treatment.E. TG levels after 24 h of fatostatin treatment.F. Scratch wound healing assay of WT and ARID1A-KO cells treated with DMSO or fatostatin (5 or 10 μmol·L-1) for 24 h. G.Quantification of wound closure rate. H. Transwell migration and invasion assays after 24 h of fatostatin treatment. I. Quantification of migrated and invaded cells.

Fig 3 Changes in the sensitivity of ARID1A-deficient NSCLC cells to fatostatin